COVID, AMYLOID, AND INFLAMMATION
Literature collection of the CovAmInf workgroup.
Editors Joshua T. Berryman Abdul Mannan Baig Artemi Bendandi Daniel Bonhenry Mattheos A.G. Koffas
Anthony Fernández-Castañeda, Peiwen Lu, Anna C. Geraghty, Eric Song, Myoung-Hwa Lee, Jamie Wood, Belgin Yalçın, Kathryn R. Taylor, Selena Dutton, Lehi Acosta-Alvarez, Lijun Ni, Daniel Contreras-Esquivel, Jeff R. Gehlhausen, Jon Klein, Carolina Lucas, Tianyang Mao, Julio Silva, Mario A. Peña-Hernández, Alexandra Tabachnikova, Takehiro Takahashi, Laura Tabacof, Jenna Tosto-Mancuso, Erica Breyman, Amy Kontorovich, Dayna McCarthy, Martha Quezado, Marco Hefti, Daniel Perl, Rebecca Folkerth, David Putrino, Avi Nath, Akiko Iwasaki, Michelle Monje
Survivors of SARS-CoV-2 infection often suffer from “brain-fog”, a general degradation of cognitive abilities. This condition shares similarities with the “chemo brain” symptoms experienced by patients after or during cancer treatment. Mice infected by SARS-CoV-2 in the nasal cavity and presenting only mild COVID-19 symptoms had an elevated cytokine profile in the cerebrospinal fluid. Elevated levels of CCL11 in the brain caused by dysregulation of oligodendrocytes resulting in myelin loss. Both “COVID-fog” and “chemo-fog” share pathophysiological similarities in the multi-cellular dysregulation.
